エーザイ、抗アミロイドβ（Aβ）プロトフィブリル抗体「レカネマブ」について、米国において、迅速承認制度に基づく早期アルツハイマー病に対する生物製剤ライセンス申請の段階的申請を完了 Eisai May 10, 2022 11:00 JST Read More
エーザイ、筋萎縮性側索硬化症（ALS）に対する高用量メコバラミン製剤の医師主導治験の結果を踏まえて、日本における新薬承認申請に向けた作業を開始 Eisai May 10, 2022 11:00 JST Read More
Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway Eisai May 10, 2022 10:23 HKT/SGT Read More
Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan Eisai May 10, 2022 10:00 HKT/SGT Read More
エーザイ、「レカネマブ」の早期アルツハイマー病当事者様に対する長期的健康アウトカムについてシミュレーションを用いた評価結果がNeurology and Therapy誌に掲載 Eisai Apr 28, 2022 10:00 JST Read More
Fujitsu and Southern Tohoku General Hospital start joint research on AI technology for detecting pancreatic cancer from non-contrast CT scans Fujitsu Ltd Apr 25, 2022 13:37 HKT/SGT Read More
Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine NEC Corporation Apr 18, 2022 15:03 HKT/SGT Read More
エーザイ、米国CMSによるアルツハイマー病治療に対するアミロイドを標的とするモノクローナル抗体に関するNational Coverage Determinationについて Eisai Apr 08, 2022 14:00 JST Read More
CEPI Partners with Japan's NEC Group to Develop Artificial Intelligence-designed Broadly Protective Betacoronavirus Vaccine NEC Corporation Apr 08, 2022 13:50 HKT/SGT Read More
BostonGene Announces $150 Million Series B Funding at a Multi-Billion Dollar Valuation, Propelling the Company to Unicorn Status NEC Corporation Apr 07, 2022 09:19 HKT/SGT Read More
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business Eisai Apr 01, 2022 13:05 HKT/SGT Read More
Marubeni, OPExPARK, Beyond Next Ventures and DENSO Collaborate to Promote DX in the Healthcare Industry Denso Apr 01, 2022 12:13 HKT/SGT Read More
エーザイ、デジタルソリューションビジネスの基盤強化と迅速な拡大をめざしたArteryexの株式取得（子会社化）に関するお知らせ Eisai Apr 01, 2022 09:00 JST Read More
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor Eisai Mar 28, 2022 21:38 HKT/SGT Read More
ギリアド・エーザイ・EAファーマ、JAK阻害剤「ジセレカ(R)錠」について、既存治療で効果不十分な中等症から重症の潰瘍性大腸炎の適応追加承認を取得 Eisai Mar 28, 2022 17:00 JST Read More
